These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution. Schallier D; Decoster L; Braeckman J; Fontaine C; Degrève J Anticancer Res; 2012 Feb; 32(2):633-41. PubMed ID: 22287756 [TBL] [Abstract][Full Text] [Related]
3. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368 [TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer. Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348 [TBL] [Abstract][Full Text] [Related]
5. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel. Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK; Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595 [TBL] [Abstract][Full Text] [Related]
6. Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer. Oudard S; Kramer G; Caffo O; Creppy L; Loriot Y; Hansen S; Holmberg M; Rolland F; Machiels JP; Krainer M BJU Int; 2015 May; 115(5):744-52. PubMed ID: 24947139 [TBL] [Abstract][Full Text] [Related]
7. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Loriot Y; Massard C; Gross-Goupil M; Di Palma M; Escudier B; Bossi A; Chauchereau A; Fizazi K Eur J Cancer; 2010 Jul; 46(10):1770-2. PubMed ID: 20483588 [TBL] [Abstract][Full Text] [Related]
8. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811 [TBL] [Abstract][Full Text] [Related]
9. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789 [TBL] [Abstract][Full Text] [Related]
10. [What is the objective of second-line chemotherapy after failure of first-line chemotherapy in hormone-resistant metastatic prostate?]. El Demery M; Pouessel D; Avancès C; Iborra F; Rebillard X; Faix A; Ségui B; Delbos O; Ayuso D; Culine S Prog Urol; 2006 Jun; 16(3):320-3. PubMed ID: 16821344 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. Di Lorenzo G; Buonerba C; Faiella A; Rescigno P; Rizzo M; Autorino R; Perdonà S; Riccardi N; Scagliorini S; Scognamiglio F; Masala D; Ferro M; Palmieri G; Aieta M; Marinelli A; Altieri V; De Placido S; Cartenì G BJU Int; 2011 Jan; 107(2):234-9. PubMed ID: 20590545 [TBL] [Abstract][Full Text] [Related]
12. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. Bracarda S; Logothetis C; Sternberg CN; Oudard S BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150 [TBL] [Abstract][Full Text] [Related]
13. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Toulmonde M; Madranges N; Brouste V; Donamaria C; MacGrogan G; Durand M; Bonnefoi H; Mauriac L; Debled M Breast Cancer Res Treat; 2012 Jul; 134(1):325-32. PubMed ID: 22531859 [TBL] [Abstract][Full Text] [Related]
15. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E; Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353 [TBL] [Abstract][Full Text] [Related]